CHARLOTTESVILLE, VA — RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced its 100th patent filing: an AI-powered ultrasound pathology detection pipeline protecting the company’s automated computer-aided diagnosis features (CADe/x) on the Accuro® XV platform. The filing marks fifteen years of continuous innovation and reinforces RIVANNA’s intellectual property estate as a vertically integrated, AI-enabled platform with FDA-cleared product lines serving multiple clinical markets.
The filing, U.S. patent application #64/080,862, describes a computer-aided detection algorithm for automated pathology identification from volumetric ultrasound imaging acquired by the Accuro XV platform that is advancing toward FDA clearance. The filing is structured as a foundational application designed to support multiple downstream continuation filings, extending claim coverage as RIVANNA advances the AI platform.
RIVANNA’s portfolio spans 100+ active issued and pending patents across more than 20 patent families, growing approximately 30% year over year, with strategic continuation depth and coverage across the United States, Europe, Japan, and China. All filings are owned or exclusively controlled by RIVANNA. Claims protect the full technology stack: AI and machine learning, cloud-based analytics infrastructure, robotics and automation, image processing and workflow, and hardware and interfaces.